Business Context and Reporting Period
Company: Greenwich LifeSciences, Inc. (GLSI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: GLSI is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The company is currently conducting the Phase III Flamingo-01 clinical trial. It operates as a single segment and has not yet generated revenue.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4,151,845) | $(11,435,485) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.30) | $(0.85) | N/A |
| Operating Expenses | $4,174,642 | $11,502,927 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,806,978 |
| Total Assets | N/A | N/A | $3,806,978 |
| Total Liabilities | N/A | N/A | $1,622,001 |
| Stockholders' Equity | N/A | N/A | $2,184,977 |
| Net Cash Used in Operating Activities | N/A | $(6,738,796) | N/A |
| Net Cash Provided by Financing Activities | N/A | $6,453,784 | N/A |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased 53% year-over-year for the three months ended September 30, 2025 ($4.17M vs. $2.73M) and 45% for the nine-month period ($11.50M vs. $7.93M).
- R&D Increase: Research and development expenses rose 54% in the quarter and 42% in the nine-month period, driven by new stock option grants and increased clinical trial costs.
- G&A Increase: General and administrative expenses increased 49% in the quarter and 65% in the nine-month period, primarily due to stock-based compensation for employees, management, and the board.
- Net Loss Expansion: Net loss for the nine months ended September 30, 2025, was $11.44M compared to $7.75M in the same period in 2024.
- Cash Position: Cash decreased by approximately $285,000 during the nine-month period, ending at $3.81M, compared to $4.09M at year-end 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to recurring net losses and negative operating cash flows. Continued operations depend on obtaining additional capital.
- Capital Raising: The company raised approximately $6.31M net through At-The-Market (ATM) offerings and $145,000 from warrant exercises during the nine months ended September 30, 2025. Subsequent to the period end (Oct 1–28, 2025), an additional $612,420 was raised via ATM.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing material weaknesses including inadequate segregation of duties and insufficient written policies.
- Related Party Transactions: Unreimbursed expenses from related parties increased to $206,834. Deferred compensation of $306,281 for senior management remains outstanding.
- Outlook: The company expects to continue incurring significant expenses and losses as it expands the Flamingo-01 trial globally and prepares for potential commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.8M cash balance against the current burn rate of approximately $6.7M per nine months to assess immediate liquidity risk.
- Capital Availability: Confirm the status of future financing plans, as the company explicitly states it requires additional capital to continue operations.
- Internal Control Remediation: Review the specific plan management is developing to remediate the material weaknesses in internal controls over financial reporting.
- Stock-Based Compensation: Analyze the impact of significant option grants (noted as a primary driver of expense increases) on future dilution and expense recognition.
- Clinical Trial Progress: Monitor updates on the Flamingo-01 Phase III trial, as the company's valuation is entirely dependent on the success of this single asset.